SAB Biotherapeutics Inc
For the period ended Mar 31, 2024. Filed May 20, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 20, 2024
SABS$3.10+2.3%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets
| March 31,2024 | December 31,2023 | |
|---|---|---|
| (Unaudited) | ||
| Assets | ||
| Current assets | ||
| Cash and cash equivalents | $14,034,162 | $56,566,066 |
| Short-term investments | 30,022,916 | — |
| Accrued interest receivable | 193,232 | — |
| Prepaid expenses and other current assets | 2,701,040 | 2,340,797 |
| Total current assets | 46,951,350 | 58,906,863 |
| Deferred issuance cost | 236,105 | — |
| Long-term prepaid insurance | 317,922 | 350,230 |
| Long-term investments | 1,235,150 | — |
| Operating lease right-of-use assets | 1,080,049 | 1,277,982 |
| Financing lease right-of-use assets | 3,647,953 | 3,669,659 |
| Property, plant and equipment, net | 17,902,553 | 19,736,519 |
| Total assets | $71,371,082 | $83,941,253 |
| Liabilities and Stockholders’ Equity | ||
| Current liabilities | ||
| Accounts payable | $1,239,943 | $945,927 |
| Notes payable | 835,467 | 1,050,849 |
| Operating lease liabilities, current portion | 542,841 | 669,946 |
| Finance lease liabilities, current portion | 134,568 | 132,004 |
| Deferred grant income | 377,835 | 1,322,410 |
| Accrued expenses and other current liabilities | 5,174,316 | 6,692,181 |
| Total current liabilities | 8,304,970 | 10,813,317 |
| Operating lease liabilities, noncurrent | 554,547 | 635,777 |
| Finance lease liabilities, noncurrent | 3,383,864 | 3,418,483 |
| Warrant liabilities | 6,306,016 | 11,774,235 |
| Total liabilities | 18,549,397 | 26,641,812 |
| Commitments and contingencies (Note 18) | ||
| Stockholders’ equity | ||
| Preferred stock; $0.0001 par value; 10,000,000 shares authorized, 42,236 shares issued and outstanding at March 31, 2024 and December 31, 2023 | 5 | 5 |
| Common stock; $0.0001 par value; 800,000,000 shares authorized at March 31, 2024 and December 31, 2023; 9,283,939 and 9,280,159 shares issued, respectively, and 9,229,274 and 9,225,494 outstanding at March 31, 2024 and December 31, 2023, respectively | 929 | 929 |
| Treasury stock, at cost; 54,665 shares held at March 31, 2024 and December 31, 2023 | (5,521,246) | (5,521,246) |
| Additional paid-in capital | 153,494,731 | 152,856,874 |
| Accumulated other comprehensive income (loss) | (63,448) | 26,420 |
| Accumulated deficit | (95,089,286) | (90,063,541) |
| Total stockholders’ equity | 52,821,685 | 57,299,441 |
| Total liabilities and stockholders’ equity | $71,371,082 | $83,941,253 |
See accompanying notes to the condensed consolidated financial statements
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.